Mangalam Drugs & Organics (NSE:MANGALAM) Earnings Power Value (EPV): ₹-36.31 (As of Mar26)


NSE:MANGALAM Mangalam Drugs & Organics Ltd NSE:MANGALAM
43 GF Score
Price ₹28.79
GF Value ₹64.85
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Mangalam Drugs & Organics Earnings Power Value (EPV)?

Mangalam Drugs & Organics NSE:MANGALAM -0.96% 43 Earnings Power Value (EPV) is ₹-36.31 as of Mar26. GuruFocus rates NSE:MANGALAM with a GF Score™ of 43/100 and a GF Value™ of ₹64.85 (Possible Value Trap). The stock has 4 warning signs investors should review.

As of Mar26, Mangalam Drugs & Organics's earnings power value is ₹-36.31. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Mangalam Drugs & Organics  (NSE:MANGALAM) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Mangalam Drugs & Organics Earnings Power Value (EPV) Related Terms


Mangalam Drugs & Organics Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Mangalam Drugs & Organics's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mangalam Drugs & Organics Earnings Power Value (EPV) Chart

Mangalam Drugs & Organics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Mangalam Drugs & Organics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:MANGALAM vs ZTS, UTHR: Earnings Power Value (EPV) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangalam Drugs & Organics Earnings Power Value (EPV) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Mangalam Drugs & Organics's Earnings Power Value (EPV) falls into.


NSE:MANGALAM
43GF Score
Mangalam Drugs & Organics Ltd NSE:MANGALAM
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mangalam Drugs & Organics Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Mangalam Drugs & Organics's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 3,461
DDA 141
Operating Margin % 0.92
SGA * 25% 0
Tax Rate % 20.09
Maintenance Capex 0
Cash and Cash Equivalents 39
Short-Term Debt 969
Long-Term Debt 86
Shares Outstanding (Diluted) 16

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = 0.92%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = ₹3,461 Mil, Average Operating Margin = 0.92%, Average Adjusted SGA = 0,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 3,461 * 0.92% +0 = ₹31.941321386 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 20.09%, and "Normalized" EBIT = ₹31.941321386 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 31.941321386 * ( 1 - 20.09% ) = ₹25.52494874598 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 141 * 0.5 * 20.09% = ₹14.206012632 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 25.52494874598 + 14.206012632 = ₹39.73096137798 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Mangalam Drugs & Organics's Average Maintenance CAPEX = ₹0 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Mangalam Drugs & Organics's current cash and cash equivalent = ₹39 Mil.
Mangalam Drugs & Organics's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 86 + 969 = ₹1054.827 Mil.
Mangalam Drugs & Organics's current Shares Outstanding (Diluted Average) = 16 Mil.

Mangalam Drugs & Organics's Earnings Power Value (EPV) for Mar26 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 39.73096137798 - 0)/ 9%+39-1054.827 )/16
=-36.31

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -36.314241616303-28.79 )/-36.314241616303
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of ₹-36.31 mean?
Mangalam Drugs & Organics (NSE:MANGALAM) has a Earnings Power Value (EPV) of ₹-36.31 as of Mar26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Mangalam Drugs & Organics and its competitors.
Is Mangalam Drugs & Organics' Earnings Power Value (EPV) too high?
Mangalam Drugs & Organics' current Earnings Power Value (EPV) is ₹-36.31. Overall, Mangalam Drugs & Organics has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mangalam Drugs & Organics' Earnings Power Value (EPV) compare to ZTS and UTHR?
Mangalam Drugs & Organics' Earnings Power Value (EPV) of ₹-36.31 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Drug Manufacturers company?
A good Earnings Power Value (EPV) depends on the Drug Manufacturers industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Mangalam Drugs & Organics and its competitors. Mangalam Drugs & Organics's current Earnings Power Value (EPV) is ₹-36.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangalam Drugs & Organics stock overvalued right now?
Based on GuruFocus' analysis, Mangalam Drugs & Organics (NSE:MANGALAM) is currently considered Possible Value Trap. The stock's GF Value™ is ₹64.85, compared to a current price of ₹28.79 — trading 55.6% below its estimated fair value. The current Earnings Power Value (EPV) is ₹-36.31. Mangalam Drugs & Organics' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Mangalam Drugs & Organics (NSE:MANGALAM), the current Earnings Power Value (EPV) is ₹-36.31 as of Mar26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mangalam Drugs & Organics (NSE:MANGALAM) Overvalued in 2026?

Based on GuruFocus' analysis, Mangalam Drugs & Organics stock appears to be undervalued. The current stock price of ₹28.79 is trading 55.6% below its estimated GF Value™ of ₹64.85. GuruFocus considers Mangalam Drugs & Organics to be Possible Value Trap.

Key valuation signals for NSE:MANGALAM:

  • Earnings Power Value (EPV): ₹-36.31
  • GF Value™: ₹64.85 vs. price of ₹28.79 (55.6% below fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the NSE:MANGALAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mangalam Drugs & Organics Business Description

Other Exchanges 532637:India
Address P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
43GF Score

Get the complete analysis for NSE:MANGALAM

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹28.79
Price
₹64.85
GF Value